- Home
- GCV vs IVVD Comparison
GCV vs IVVD Comparison
Compare GCV & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCV
- IVVD
- Stock Information
- Founded
- GCV 1988
- IVVD 2020
- Country
- GCV United States
- IVVD United States
- Employees
- GCV N/A
- IVVD N/A
- Industry
- GCV Finance/Investors Services
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- GCV Finance
- IVVD Health Care
- Exchange
- GCV Nasdaq
- IVVD Nasdaq
- Market Cap
- GCV 72.3M
- IVVD 69.0M
- IPO Year
- GCV N/A
- IVVD 2021
- Fundamental
- Price
- GCV $3.73
- IVVD $1.01
- Analyst Decision
- GCV
- IVVD Strong Buy
- Analyst Count
- GCV 0
- IVVD 3
- Target Price
- GCV N/A
- IVVD $5.85
- AVG Volume (30 Days)
- GCV 57.9K
- IVVD 3.1M
- Earning Date
- GCV 01-01-0001
- IVVD 05-15-2025
- Dividend Yield
- GCV 13.04%
- IVVD N/A
- EPS Growth
- GCV N/A
- IVVD N/A
- EPS
- GCV N/A
- IVVD N/A
- Revenue
- GCV N/A
- IVVD $36,688,000.00
- Revenue This Year
- GCV N/A
- IVVD $606.63
- Revenue Next Year
- GCV N/A
- IVVD $83.30
- P/E Ratio
- GCV N/A
- IVVD N/A
- Revenue Growth
- GCV N/A
- IVVD N/A
- 52 Week Low
- GCV $3.15
- IVVD $0.35
- 52 Week High
- GCV $4.58
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- GCV 55.70
- IVVD 64.36
- Support Level
- GCV $3.62
- IVVD $0.81
- Resistance Level
- GCV $3.71
- IVVD $1.00
- Average True Range (ATR)
- GCV 0.05
- IVVD 0.10
- MACD
- GCV 0.00
- IVVD 0.02
- Stochastic Oscillator
- GCV 61.06
- IVVD 82.72
About GCV Gabelli Convertible and Income Securities Fund Inc. (The)
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.